FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322753879> ?p ?o ?g. }

• W4322753879 endingPage "102627" @default.
• W4322753879 startingPage "102627" @default.
• W4322753879 abstract "Prostate cancer (PCa) remains one of the clinically relevant pathologies that needs pragmatic and effective treatment approaches. The current study aimed to evaluate the anticancer potential of epigallocatechin gallate (EGCG) and EGCG-loaded nanoparticles (EGCG NP) for the treatment of prostate cancer in in-vitro 3D spheroid model. The EGCG NPs was synthesized by using polymeric method as reported in our previous study. A 3D spheroid assay was conducted using human prostate specific cell lines (PC3 and 22Rv1) cultured on poly-HEMA-covered plates at different time points. Once formed, the spheroids were treated with either EGCG alone or with EGCG NPs continuously for 6 days. Simultaneously, specific controls were also taken for comparison purpose. CellROX dye was used to quantitate the formation of reactive oxygen species (ROS) in response to EGCG and EGCG NPs to 22Rv1 and PC3, 3D spheroids. The treated spheroids were also evaluated to measure modulation in mitochondrial membrane potential and the quantification of apoptotic and live cells using a flow cytometer. The spheroid sizes of both studied cell lines were found to be significantly (p < 0.05) reduced after the treatment with EGCG and its nanoformulation. The significant increase in ROS formation was observed in PC3 cells in response to EGCG and EGCG-NPs treatment. However, no significant change in ROS formation was observed in 22Rv1 cells. Similarly, both compounds (EGCG and EGCG NPs) did not show any significant changes in mitochondrial membrane potential in 22Rv1 and PC3 spheroids. Interestingly, EGCG treatment showed a significant change between live and apoptotic cells in both 22Rv1 and PC3 spheroids but its nanoformulation didn’t show any significant change in the number of apoptotic and live cells. Our study observed a significant anticancer potential of EGCG and EGCG NPs at clinically relevant doses highlighting the possible advantage of 3D spheroid model specifically in our studied cancer cells. However, further preclinical in vivo studies are recommended in a suitable model to decipher our in vitro data and exploit EGCG and EGCG NPs against prostate cancer. Our results indicate the anticancer efficacy of EGCG and EGCG NPs in 3D spheroids of PCa cell lines." @default.
• W4322753879 created "2023-03-03" @default.
• W4322753879 creator A5026792480 @default.
• W4322753879 creator A5037323486 @default.
• W4322753879 creator A5040046127 @default.
• W4322753879 creator A5041781745 @default.
• W4322753879 creator A5046592525 @default.
• W4322753879 creator A5059560949 @default.
• W4322753879 creator A5089477910 @default.
• W4322753879 date "2023-05-01" @default.
• W4322753879 modified "2023-10-11" @default.
• W4322753879 title "Comparative efficacy of epigallocatechin gallate and its nano-formulation in prostate cancer 3D spheroids model" @default.
• W4322753879 cites W2065443692 @default.
• W4322753879 cites W2263453062 @default.
• W4322753879 cites W2343057138 @default.
• W4322753879 cites W2401987140 @default.
• W4322753879 cites W2518642608 @default.
• W4322753879 cites W2524269826 @default.
• W4322753879 cites W2607722982 @default.
• W4322753879 cites W2612323044 @default.
• W4322753879 cites W2762026651 @default.
• W4322753879 cites W2773927148 @default.
• W4322753879 cites W2795966786 @default.
• W4322753879 cites W2888438700 @default.
• W4322753879 cites W2914847955 @default.
• W4322753879 cites W2943197695 @default.
• W4322753879 cites W2947179537 @default.
• W4322753879 cites W2963971611 @default.
• W4322753879 cites W2985727825 @default.
• W4322753879 cites W2996188048 @default.
• W4322753879 cites W2996770601 @default.
• W4322753879 cites W3016106576 @default.
• W4322753879 cites W3045371965 @default.
• W4322753879 cites W3082990138 @default.
• W4322753879 cites W3084214017 @default.
• W4322753879 cites W3097865616 @default.
• W4322753879 cites W3111112091 @default.
• W4322753879 cites W3126550244 @default.
• W4322753879 cites W3128646645 @default.
• W4322753879 cites W3128687569 @default.
• W4322753879 cites W3136843699 @default.
• W4322753879 cites W3167737356 @default.
• W4322753879 cites W3199190638 @default.
• W4322753879 cites W4200318919 @default.
• W4322753879 cites W4205420619 @default.
• W4322753879 cites W4214870790 @default.
• W4322753879 cites W4226077044 @default.
• W4322753879 cites W4281606197 @default.
• W4322753879 cites W4284978145 @default.
• W4322753879 cites W4289522876 @default.
• W4322753879 cites W4294128124 @default.
• W4322753879 doi "https://doi.org/10.1016/j.jksus.2023.102627" @default.
• W4322753879 hasPublicationYear "2023" @default.
• W4322753879 type Work @default.
• W4322753879 citedByCount "1" @default.
• W4322753879 countsByYear W43227538792023 @default.
• W4322753879 crossrefType "journal-article" @default.
• W4322753879 hasAuthorship W4322753879A5026792480 @default.
• W4322753879 hasAuthorship W4322753879A5037323486 @default.
• W4322753879 hasAuthorship W4322753879A5040046127 @default.
• W4322753879 hasAuthorship W4322753879A5041781745 @default.
• W4322753879 hasAuthorship W4322753879A5046592525 @default.
• W4322753879 hasAuthorship W4322753879A5059560949 @default.
• W4322753879 hasAuthorship W4322753879A5089477910 @default.
• W4322753879 hasBestOaLocation W43227538791 @default.
• W4322753879 hasConcept C121608353 @default.
• W4322753879 hasConcept C12554922 @default.
• W4322753879 hasConcept C126322002 @default.
• W4322753879 hasConcept C153911025 @default.
• W4322753879 hasConcept C175369904 @default.
• W4322753879 hasConcept C185592680 @default.
• W4322753879 hasConcept C190283241 @default.
• W4322753879 hasConcept C202751555 @default.
• W4322753879 hasConcept C2777192995 @default.
• W4322753879 hasConcept C2778004101 @default.
• W4322753879 hasConcept C2780192828 @default.
• W4322753879 hasConcept C48349386 @default.
• W4322753879 hasConcept C502942594 @default.
• W4322753879 hasConcept C553184892 @default.
• W4322753879 hasConcept C55493867 @default.
• W4322753879 hasConcept C70899900 @default.
• W4322753879 hasConcept C71924100 @default.
• W4322753879 hasConcept C86803240 @default.
• W4322753879 hasConcept C96232424 @default.
• W4322753879 hasConceptScore W4322753879C121608353 @default.
• W4322753879 hasConceptScore W4322753879C12554922 @default.
• W4322753879 hasConceptScore W4322753879C126322002 @default.
• W4322753879 hasConceptScore W4322753879C153911025 @default.
• W4322753879 hasConceptScore W4322753879C175369904 @default.
• W4322753879 hasConceptScore W4322753879C185592680 @default.
• W4322753879 hasConceptScore W4322753879C190283241 @default.
• W4322753879 hasConceptScore W4322753879C202751555 @default.
• W4322753879 hasConceptScore W4322753879C2777192995 @default.
• W4322753879 hasConceptScore W4322753879C2778004101 @default.
• W4322753879 hasConceptScore W4322753879C2780192828 @default.
• W4322753879 hasConceptScore W4322753879C48349386 @default.
• W4322753879 hasConceptScore W4322753879C502942594 @default.
• W4322753879 hasConceptScore W4322753879C553184892 @default.

• next